uu.seUppsala universitets publikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
BETA
Tsolakis, Apostolos V.
Alternativa namn
Publikationer (10 of 29) Visa alla publikationer
Daskalakis, K., Chatzelis, E., Tsoli, M., Papadopoulou-Marketou, N., Dimitriadis, G. K., Tsolakis, A. V. & Kaltsas, G. (2019). Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. Endocrine (Basingstoke), 64(2), 384-392
Öppna denna publikation i ny flik eller fönster >>Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms
Visa övriga...
2019 (Engelska)Ingår i: Endocrine (Basingstoke), ISSN 1355-008X, E-ISSN 1559-0100, Vol. 64, nr 2, s. 384-392Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: Our aim was to assess the prevalence of endocrine paraneoplastic syndromes (EPNS) in neuroendocrine neoplasms (NENs) and estimate its impact on patient outcomes.

Design: This is a retrospective analysis of 834 patients with NENs (611 gastrointestinal, 166 thoracic, 57 of unknown and various other primary origin). We included 719 consecutive NEN patients treated at EKPA-Laiko Hospital, Athens, Greece and 115 patients with lung carcinoid (LC) treated at Uppsala University Hospital, Uppsala, Sweden. EPNS diagnosis was based on standard criteria.

Methods: Twenty-one patients with EPNS were detected: 16 with ectopic Cushing's syndrome (ECS), one with hypercalcaemia due to parathyroid hormone-related protein (PTHrP) secretion, three with hypercalcitonaemia and one patient with dual secretion of calcitonin and beta-human chorionic gonadotropin (-HCG). All tumours were well-differentiated; 10 patients had Stage IV disease at diagnosis.

Results: The prevalence of EPNS in the Greek cohort was 1.9%, whereas that of ECS among LC patients in both centres was 6.7%. Median overall survival (OS) for patients with EPNS was 160.7 months (95%CI, 86-235.4) and median event-free survival (EFS) was 25.9 months (95%CI, 0-57.2). Patients presenting with EPNS prior to NEN diagnosis had longer EFS compared to patients with synchronous or metachronous EPNS (log-rank P=0.013). Patients with ECS of extra-thoracic origin demonstrated shorter OS and EFS compared to patients with ECS of lung or thymic origin (log-rank P=0.001 and P<0.001, respectively). LC patients with and without ECS were comparable in 5-year and 10-year OS rates (66.7% and 33.3% versus 89.8% and 60.2%, respectively; 95%CI [189.6-300.4 months], log-rank P=0.94) and in median EFS, 67 versus 183 months, 95%CI [50.5-207.5], log-rank P=0.12).

Conclusion: EPNS are relatively rare in patients with NENs and mainly concern well-differentiated tumours of the foregut. Among patients with EPNS, LC-related ECS may not adversely affect patient outcomes when diagnosed prior to NEN and effectively been treated.

Ort, förlag, år, upplaga, sidor
SPRINGER, 2019
Nyckelord
Paraneoplastic syndrome, Neuroendocrine tumours, Ectopic Cushing's syndrome, Hypercalcitonaemia, PTHrP secretion
Nationell ämneskategori
Endokrinologi och diabetes Cancer och onkologi
Identifikatorer
urn:nbn:se:uu:diva-386165 (URN)10.1007/s12020-018-1773-3 (DOI)000468840200021 ()30280284 (PubMedID)
Anmärkning

De två första författarna delar förstaförfattarskapet.

Tillgänglig från: 2019-06-20 Skapad: 2019-06-20 Senast uppdaterad: 2019-06-20Bibliografiskt granskad
Georgantzi, K., Tsolakis, A. V., Jakobson, Å., Christofferson, R., Tiensuu Janson, E. & Grimelius, L. (2019). Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma. Endocrine pathology, 30(3), 173-179
Öppna denna publikation i ny flik eller fönster >>Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma
Visa övriga...
2019 (Engelska)Ingår i: Endocrine pathology, ISSN 1046-3976, E-ISSN 1559-0097, Vol. 30, nr 3, s. 173-179Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Neuroblastoma (NB), the most common extracranial cancer in childhood, exhibits neuroendocrine (NE) differentiation. Two well-established NE markers, chromogranin A (CgA) and synaptophysin (syn), are used in the histopathological diagnostics. Our aims were to explore if the NE markers synaptic vesicle protein 2 (SV2) and vesicular monoamine transporter 1 (VMAT1) and 2 (VMAT2) also are expressed in human NB and if so, evaluate their usefulness in NB histopathological diagnostics. Tumor specimens from 21 NB patients, before and/or after chemotherapy, were immunostained for CgA, syn, SV2, VMAT1, and VMAT2. Clinical data was extracted from patients' records. SV2 was highly expressed in NB, as was CgA while syn was less frequently expressed compared to the other two. Both VMATs were expressed in several NB, VMAT2 in more cases than VMAT1 and its expression was similar to syn. Chemotherapy did not affect the immunoreactivity in an obvious way. SV2 was highly expressed in NB and can thus be useful marker in NB diagnostics. VMAT1 and VMAT2 were also expressed in NB but similar to syn less reliable as tumor markers.

Nyckelord
neuroblastoma, neuroendocrine, immunohistochemistry, urine-dopamine, urine-HVA, urine-VMA, markers
Nationell ämneskategori
Kirurgi Pediatrik Cancer och onkologi
Identifikatorer
urn:nbn:se:uu:diva-364674 (URN)10.1007/s12022-019-09584-3 (DOI)000481425400001 ()31317476 (PubMedID)
Tillgänglig från: 2018-10-31 Skapad: 2018-10-31 Senast uppdaterad: 2019-09-25Bibliografiskt granskad
Daskalakis, K., Kaltsas, G., Öberg, K. & Tsolakis, A. V. (2018). Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers. Neuroendocrinology, 107(4), 355-365
Öppna denna publikation i ny flik eller fönster >>Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers
2018 (Engelska)Ingår i: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 107, nr 4, s. 355-365Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background/Aims: Lung carcinoids (LCs) are often diagnosed at an early stage and surgical intervention becomes the next phase of treatment. To date, there is lack of long-term follow-up data after surgery and prognostication based on WHO classification criteria and evolving prognostic markers, particularly the expression of somatostatin receptors (SSR).

Methods: We included 102 consecutive patients (72 women; age at baseline 51 ± 16 years [mean ± SD]) with LCs, who underwent thoracic surgery (n = 99) and/or laser treatment (n = 8). Hospital charts were reviewed for clinico-pathological parameters. Immunohistochemical (IHC) expression of SSR1–5 and other novel markers were studied with regard to their prognostic value.

Results: Five- and 10-year overall survival (OS) was 96 and 83% respectively; relative survival (RS) was 101 and 93% respectively; and event-free survival (EFS) was 80 and 67% respectively. Independent prognostic factors for OS, RS and/or EFS were age at diagnosis, histopathological type and the presence of ipsilateral mediastinal subcarinal lymph node metastases. Macro-radicality of resective surgery and its extent were associated with increased OS and EFS. The IHC expression of SSR1–5 and other novel markers was not associated with OS or EFS.

Conclusion: The long-term outcome of surgically treated patients with LCs is favourable. Age, histopathological type and ipsilateral mediastinal subcarinal lymph node status at baseline were independent prognostic factors for survival and disease recurrence or progression. The extent of surgery and operative macro-radicality also had an impact on prognosis. None of the IHC markers tested appeared to be associated with disease prognosis.

Nyckelord
Lung carcinoid, Overall, Relative, Event-free survival, Thoracic surgery, Laser treatment
Nationell ämneskategori
Cancer och onkologi Kirurgi
Identifikatorer
urn:nbn:se:uu:diva-375861 (URN)10.1159/000493944 (DOI)000456061100004 ()30244255 (PubMedID)
Tillgänglig från: 2019-02-01 Skapad: 2019-02-01 Senast uppdaterad: 2019-02-01Bibliografiskt granskad
Kanakis, G., Grimelius, L., Spathis, A., Tringidou, R., Rassidakis, G. Z., Öberg, K., . . . Tsolakis, A. V. (2015). Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role. Neuroendocrinology, 101(3), 211-222
Öppna denna publikation i ny flik eller fönster >>Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role
Visa övriga...
2015 (Engelska)Ingår i: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 101, nr 3, s. 211-222Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: The expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance as somatostatin analogues and dopamine agonists can be used for their localization and/or treatment. The objective of this study is to examine the expression of the five SSTR subtypes and DR2 in lung carcinoids (LCs). Methods: We conducted a retrospective study of 119 LCs from 106 patients [typical carcinoids (TCs): n = 100, and atypical carcinoids (ACs): n = 19]. The expression of all five SSTR subtypes and DR2 was evaluated immunohistochemically and correlated to clinicopathological data. In a subgroup of cases, receptor expression was further analyzed using semiquantitative RT-PCR. Results: SSTR2A was the SSTR subtype most frequently expressed immunohistochemically (72%), followed by SSTR1 (63%), SSTR5 (40%), and SSTR3 (20%), whereas SSTR4 was negative. DR2 was expressed in 74% and co-expressed with SSTR1 in 56%, with SSTR2A in 59%, with SSTR3 in 19%, and with SSTR5 in 37% of the tumors. Receptor expression was not related to the histological subtype, tumor aggressiveness (disease extent/grading) or functionality; however, DR2 was expressed more frequently in ACs than TCs (95 vs. 70%, p = 0.017). In a subset of patients, RT-PCR findings highly suggested that the expression of SSTR2A, SSTR3, DR2, and to a lesser extent that of SSTR1 and SSTR5 is the outcome of increased gene transcription. Conclusions: The high and variable immunohistochemical expression of the majority of SSTRs along with their co-expression with DR2 in LCs provides a rationale for their possible treatment with agents that target these receptors.

Nyckelord
Somatostatin receptor subtypes, Dopamine receptor 2, Immunohistochemistry, Lung carcinoids
Nationell ämneskategori
Endokrinologi och diabetes Neurovetenskaper
Identifikatorer
urn:nbn:se:uu:diva-258556 (URN)10.1159/000381061 (DOI)000356490100003 ()25765100 (PubMedID)
Tillgänglig från: 2015-07-15 Skapad: 2015-07-15 Senast uppdaterad: 2018-01-11Bibliografiskt granskad
Tsolakis, A. V., Grimelius, L., Granerus, G., Stridsberg, M., Falkmer, S. E. & Janson, E. T. (2015). Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours. World Journal of Gastroenterology, 21(47), 13240-13249
Öppna denna publikation i ny flik eller fönster >>Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours
Visa övriga...
2015 (Engelska)Ingår i: World Journal of Gastroenterology, ISSN 1007-9327, E-ISSN 2219-2840, Vol. 21, nr 47, s. 13240-13249Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

AIM:

To study histidine decarboxylase (HDC) expression in normal and neoplastic gastric neuroendocrine cells in relationship to the main histamine metabolite.

METHODS:

Control tissues from fundus (n = 3) and corpus (n = 3) mucosa of six patients undergoing operations for gastric adenocarcinoma, biopsy and/or gastric surgical specimens from 64 patients with primary gastric neuroendocrine tumours (GNETs), as well as metastases from 22 of these patients, were investigated using conventional immunohistochemistry and double immunofluorescence with commercial antibodies vs vesicular monoamine transporter 2 (VMAT-2), HDC and ghrelin. The urinary excretion of the main histamine metabolite methylimidazoleacetic acid (U-MeImAA) was determined using high-performance liquid chromatography in 27 of the 64 patients.

RESULTS:

In the gastric mucosa of the control tissues, co-localization studies identified neuroendocrine cells that showed immunoreactivity only to VMAT-2 and others with reactivity only to HDC. A third cell population co-expressed both antigens. There was no co-expression of HDC and ghrelin. Similar results were obtained in the foci of neuroendocrine cell hyperplasia associated with chronic atrophic gastritis type A and also in the tumours. The relative incidence of the three aforementioned markers varied in the tumours that were examined using conventional immunohistochemistry. All of these GNETs revealed both VMAT-2 and HDC immunoreactivity, and their metastases showed an immunohistochemical pattern and frequency similar to that of their primary tumours. In four patients, increased U-MeImAA excretion was detected, but only two of the patients exhibited related endocrine symptoms.

CONCLUSION:

Human enterochromaffin-like cells appear to partially co-express VMAT-2 and HDC. Co-expression of VMAT-2 and HDC might be required for increased histamine production in patients with GNETs.

Nyckelord
Enterochromaffin-like cells, High performance liquid chromatography, Gastric neuroendocrine tumours, Histidine decarboxylase, Immunohistochemistry, Urinary excretion of the main histamine metabolite methylimidazoleacetic acid, Vesicular monoamine transporter 2
Nationell ämneskategori
Gastroenterologi
Identifikatorer
urn:nbn:se:uu:diva-274442 (URN)10.3748/wjg.v21.i47.13240 (DOI)000366889600004 ()26715806 (PubMedID)
Tillgänglig från: 2016-01-21 Skapad: 2016-01-21 Senast uppdaterad: 2017-11-30Bibliografiskt granskad
Tsolakis, A., James, P., Zhang, M., Belletrutti, P., Mohamed, R., Roberts, D. & Heitman, S. (2015). Incremental Benefit of Preoperative Endoscopic Ultrasound for the Detection of Pancreatic Neuroendocrine Tumors: A Meta-Analysis. Paper presented at 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 11-13, 2015, Barcelona, SPAIN. Neuroendocrinology, 102(1-2), 116-116
Öppna denna publikation i ny flik eller fönster >>Incremental Benefit of Preoperative Endoscopic Ultrasound for the Detection of Pancreatic Neuroendocrine Tumors: A Meta-Analysis
Visa övriga...
2015 (Engelska)Ingår i: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 102, nr 1-2, s. 116-116Artikel i tidskrift, Meeting abstract (Övrigt vetenskapligt) Published
Nyckelord
pancreatic neuroendocrine tumor, radiological investigation, incremental benefit, endoscopic ultrasound
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:uu:diva-266079 (URN)10.1159/000431385 (DOI)000361683500108 ()
Konferens
12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 11-13, 2015, Barcelona, SPAIN
Tillgänglig från: 2015-11-05 Skapad: 2015-11-05 Senast uppdaterad: 2017-12-01Bibliografiskt granskad
James, P. D., Tsolakis, A. V., Zhang, M., Belletrutti, P. J., Mohamed, R., Roberts, D. J. & Heitman, S. J. (2015). Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointestinal Endoscopy, 81(4), 848-+
Öppna denna publikation i ny flik eller fönster >>Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis
Visa övriga...
2015 (Engelska)Ingår i: Gastrointestinal Endoscopy, ISSN 0016-5107, E-ISSN 1097-6779, Vol. 81, nr 4, s. 848-+Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Background: Current guidelines recommend CT scan or magnetic resonance imaging as the initial imaging modalities for the work-up of suspected pancreatic neuroendocrine tumors (PNETs). Objective: To determine the incremental benefit of preoperative EUS (IBEUS) for the detection of suspected PNETs after other investigative modalities have been attempted. Design: This systematic review searched MEDLINE, EMBASE, bibliographies of included articles, and conference proceedings for studies reporting original data regarding the preoperative detection of PNETs. Pooled IBEUS was calculated by using random effects models. Heterogeneity was explored by using stratified meta-analysis and meta-regression. Evidence of small-study effects was assessed by using funnel plots and the Begg test. Patients: Patients with suspected PNETs. Interventions: EUS evaluation. Main Outcome Measurements: The pooled IBEUS for the detection of PNETs after CT scan, with or without additional investigative modalities. Results: Among 4505 citations identified, we included 17 cohort studies (612 patients). EUS identified PNETs in 97% of cases. Improved PNET identification with EUS was observed in all of the studies. After adjusting for small-study effects, meta-analysis showed that EUS alone could identify PNETs in approximately 1 in 4 patients (adjusted IBEUS 26%; 95% confidence interval, 17%-37%). The pooled IBEUS varied based on the study design, study size, type of CT scan used, and the number of modalities used prior to EUS. Limitations: The majority of included studies were retrospective. Small-study effects were observed. Conclusion: Preoperative EUS is associated with an increase in PNET detection after other modalities are attempted.

Nationell ämneskategori
Gastroenterologi
Identifikatorer
urn:nbn:se:uu:diva-252458 (URN)10.1016/j.gie.2014.12.031 (DOI)000351668700006 ()25805462 (PubMedID)
Tillgänglig från: 2015-05-07 Skapad: 2015-05-07 Senast uppdaterad: 2017-12-04Bibliografiskt granskad
Diakatou, E., Alexandraki, K. I., Tsolakis, A. V., Kontogeorgos, G., Chatzellis, E., Leonti, A. & Kaltsas, G. A. (2015). Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clinical Endocrinology, 83(3), 420-428
Öppna denna publikation i ny flik eller fönster >>Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores
Visa övriga...
2015 (Engelska)Ingår i: Clinical Endocrinology, ISSN 0300-0664, E-ISSN 1365-2265, Vol. 83, nr 3, s. 420-428Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

ContextThe expression of somatostatin (sstr1-5) and dopamine (DR) receptors in neuroendocrine neoplasms (NENs) facilitates diagnosis by tumour visualization with somatostatin receptor scintigraphy (SRS) and directs towards specific treatment with peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues. ObjectiveTo investigate the co-expression of sstrs, D2R in relation to pre-operative SRSs in NENs. DesignProspective two-centre study. Patients and measurementsWe analysed pre-operative SRS of 60 patients [44 with gastrointestinal (GI) NENs and 16 with lung NENs] and compared SRS results with immunohistochemical (IHC) reactivity for sstr2, sstr3, sstr5 in sample tissues from primary (n=54) and metastatic (n=27) lesions and IHC reactivity for D2R in 23 samples from primary GI-NENs lesions. ResultsSstr2 was the commonest sstr expressed (654%) and was co-expressed with sstr3 and sstr5 in 321% and 247% of the specimens, respectively. In 67 of 81 specimens (827%), there was concordance of sstr2 immunohistochemistry with SRS findings (P<0001). D2R was expressed in only 8 of 23 (348%) GI-NENs while was co-expressed with sstr2 in all cases. SRS grade, as per Krenning scale, was higher in metastatic foci, large-size (>2cm) tumours and GI-NENs, whereas sstr2 intensity was greater in GI compared to lung NENs. SRS grade showed higher correlation with sstr2 (r=06, P<0001) and D2R (r=05, P<0001) IHC intensity scores than tumour size (r=04, P<0001) and sstr3 (r=04, P<0001) intensity score. ConclusionsSstr2 IHC expression and SRS are useful tools for the diagnosis and management of NENs because they display a high concordance. IHC expression of DR2 seems to be of potential clinical significance in GI-NENs tumours.

Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer
urn:nbn:se:uu:diva-262956 (URN)10.1111/cen.12775 (DOI)000360459600022 ()25808161 (PubMedID)
Tillgänglig från: 2015-09-29 Skapad: 2015-09-23 Senast uppdaterad: 2017-12-01Bibliografiskt granskad
Spargias, K., Bouboulis, N., Halapas, A., Chrissoheris, M., Skardoutsos, S., Nikolaou, J., . . . Pattakos, S. (2015). Transaortic aortic valve replacement using the Edwards Sapien-XT Valve and the Medtronic CoreValve: initial experience. Hellenic Journal of Cardiology, 55(4), 288-293
Öppna denna publikation i ny flik eller fönster >>Transaortic aortic valve replacement using the Edwards Sapien-XT Valve and the Medtronic CoreValve: initial experience
Visa övriga...
2015 (Engelska)Ingår i: Hellenic Journal of Cardiology, ISSN 1109-9666, Vol. 55, nr 4, s. 288-293Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

INTRODUCTION: Transcatheter aortic valve replacement (TAVR) is now an established treatment for certain patients with severe aortic valve stenosis (AS). However, as the number of patients screened for TAVR increases, many are found to have absolutely no option for peripheral artery access. Transaortic valve replacement (TAoVR) has been proposed as a new alternative route in patients deemed unsuitable for conventional approaches. We present our first series of TAoVR cases using the Edwards Sapien-XT and the Medtronic CoreValve prostheses.

METHODS: Twenty-five (25) symptomatic patients (mean age 78 ± 8 years, mean logistic EuroSCORE I 25 ± 11%) with severe AS underwent TAoVR using the Sapien-XT valve (10 patients) or the CoreValve (15 patients).

RESULTS: The mean fluoroscopy time was 15.6 ± 4.2 minutes, the mean time in the intensive care unit was 1.9 ± 1.0 days, and the mean hospital stay was 6.4 ± 1.6 days. The mean effective aortic valve area increased (from 0.68 ± 0.15 cm(2) to 1.82 ± 0.34 cm(2), p<0.001) and the mean transvalvular pressure gradient declined (from 48 ± 15 mmHg to 9 ± 5 mmHg, p<0.05) post implantation. The procedural mortality was 0% and the in-hospital mortality was 4% (one death at day 3 due to cardiogenic shock). The mean NYHA functional class improved from 3.2 ± 0.4 to 1.5 ± 0.9 at 30 days.

CONCLUSIONS: Our initial experience with the TAoVR approach using both the Edwards Sapien-XT and the Medtronic CoreValve prosthesis demonstrated that it could be performed safely, resulting in substantial acute echocardiographic and early clinical improvement.

Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer
urn:nbn:se:uu:diva-244251 (URN)000344038100004 ()25039024 (PubMedID)
Tillgänglig från: 2015-02-13 Skapad: 2015-02-13 Senast uppdaterad: 2017-12-04Bibliografiskt granskad
Lyros, I., Fora, E., Damaskos, S., Stanko, P. & Tsolakis, A. (2014). An incidental finding on a diagnostic CBCT: a case report. Australian orthodontic journal, 30(1), 67-71
Öppna denna publikation i ny flik eller fönster >>An incidental finding on a diagnostic CBCT: a case report
Visa övriga...
2014 (Engelska)Ingår i: Australian orthodontic journal, ISSN 0587-3908, Vol. 30, nr 1, s. 67-71Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

It is known that Cone Beam Computed Tomography (CBCT) provides reliable spatial data and has many clinical applications for dental and particularly orthodontic patients. The present article provides a short review of the literature and reports an unusual CBCT finding in an orthodontic patient referred for the assessment of impacted upper canines. A unilateral lesion in the left maxillary sinus, was an incidental finding. Following a histological examination, which revealed unilateral nasal polyps, surgical removal was performed as the treatment of choice.

Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer
urn:nbn:se:uu:diva-244252 (URN)000339592800010 ()24968648 (PubMedID)
Tillgänglig från: 2015-02-13 Skapad: 2015-02-13 Senast uppdaterad: 2015-04-24Bibliografiskt granskad
Organisationer

Sök vidare i DiVA

Visa alla publikationer